{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:27:11Z","timestamp":1794565631953,"version":"4.9.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Government of Catalonia Agency for Administration of University and Research Grants","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Government of Catalonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004412","name":"Human Frontier Science Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.neo.2025.101143","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T19:20:02Z","timestamp":1740424802000},"page":"101143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer"],"prefix":"10.1016","volume":"62","author":[{"given":"Travis Vander","family":"Steen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-8823","authenticated-orcid":false,"given":"Cristina","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-1600","authenticated-orcid":false,"given":"Guillem","family":"Casadevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9477-0350","authenticated-orcid":false,"given":"Eila","family":"Serrano-Herv\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Cuy\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-0423","authenticated-orcid":false,"given":"Sara","family":"Verdura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kemble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-5040","authenticated-orcid":false,"given":"Robert","family":"McWilliams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Osuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Billadeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-4561","authenticated-orcid":false,"given":"Javier A.","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Lupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2025.101143_bib0001","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101143_bib0002","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00000658-200301000-00011","article-title":"Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients","volume":"237","author":"Lim","year":"2003","journal-title":"Ann. Surg."},{"key":"10.1016\/j.neo.2025.101143_bib0003","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/cncr.22916","article-title":"Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume","volume":"110","author":"Bilimoria","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.neo.2025.101143_bib0004","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/bjs.4484","article-title":"Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma","volume":"91","author":"Wagner","year":"2004","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.neo.2025.101143_bib0005","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic cancer","volume":"362","author":"Hidalgo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101143_bib0006","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101143_bib0007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.neo.2025.101143_bib0008","doi-asserted-by":"crossref","first-page":"dju413","DOI":"10.1093\/jnci\/dju413","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.neo.2025.101143_bib0009","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00280-015-2683-1","article-title":"Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study","volume":"75","author":"Petrioli","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.neo.2025.101143_bib0010","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101143_bib0011","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101143_bib0012","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"Canadian cancer trials group and the unicancer-GI\u2013PRODIGE group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101143_bib0013","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ijc.11679","article-title":"Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis","volume":"109","author":"Schniewind","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.neo.2025.101143_bib0014","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1476-4598-2-6","article-title":"Apoptosis: targets in pancreatic cancer","volume":"2","author":"Westphal","year":"2003","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neo.2025.101143_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers3010001","article-title":"The role of apoptosis in the pathology of pancreatic cancer","volume":"3","author":"Samm","year":"2010","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2025.101143_bib0016","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.canlet.2010.10.015","article-title":"Targeting apoptosis pathways in pancreatic cancer","volume":"332","author":"Arlt","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.neo.2025.101143_bib0017","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1007\/s10620-018-5253-7","article-title":"BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo","volume":"63","author":"Zhou","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.neo.2025.101143_bib0018","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tranon.2019.01.009","article-title":"Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma","volume":"12","author":"Duan","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.neo.2025.101143_bib0019","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-14-3013","article-title":"Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline","volume":"75","author":"Quinn","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101143_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2021.118987","article-title":"It's time to die: BH3 mimetics in solid tumors","volume":"1868","author":"Kehr","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.neo.2025.101143_bib0021","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.tcb.2013.08.003","article-title":"Mitochondria: gatekeepers of response to chemotherapy","volume":"23","author":"Sarosiek","year":"2013","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.neo.2025.101143_bib0022","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc2615","article-title":"Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics","volume":"9","author":"Cragg","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2025.101143_bib0023","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1111\/febs.13714","article-title":"Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise","volume":"283","author":"Sarosiek","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.neo.2025.101143_bib0024","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neo.2025.101143_bib0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death. Differ."},{"key":"10.1016\/j.neo.2025.101143_bib0026","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2025.101143_bib0027","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/2159-8290.CD-21-1334","article-title":"Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics","volume":"12","author":"Montero","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2025.101143_bib0028","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2025.101143_bib0029","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","article-title":"BH3 profiling\u2013measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions","volume":"332","author":"Del Gaizo Moore","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.neo.2025.101143_bib0030","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/bjc.2016.49","article-title":"BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells","volume":"114","author":"Butterworth","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2025.101143_bib0031","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/s41418-019-0391-9","article-title":"BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics","volume":"27","author":"Villalobos-Ortiz","year":"2020","journal-title":"Cell Death. Differ."},{"key":"10.1016\/j.neo.2025.101143_bib0032","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Gomez-Bougie","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.neo.2025.101143_bib0033","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41419-021-04029-4","article-title":"Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer","volume":"12","author":"Potter","year":"2021","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.neo.2025.101143_bib0034","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.neo.2025.101143_bib0035","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","article-title":"Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy","volume":"160","author":"Montero","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.neo.2025.101143_bib0036","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.25692","article-title":"Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy","volume":"95","author":"Garcia","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.neo.2025.101143_bib0037","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1021\/acs.chemrev.1c00147","article-title":"Animal fatty acid synthase: a chemical nanofactory","volume":"121","author":"Paiva","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.neo.2025.101143_bib0038","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2025.101143_bib0039","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrc.2016.89","article-title":"The multifaceted roles of fatty acid synthesis in cancer","volume":"16","author":"R\u00f6hrig","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2025.101143_bib0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","article-title":"Reprogramming of fatty acid metabolism in cancer","volume":"122","author":"Koundouros","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2025.101143_bib0041","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41389-022-00420-8","article-title":"Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance","volume":"11","author":"Vasseur","year":"2022","journal-title":"Oncogenesis"},{"key":"10.1016\/j.neo.2025.101143_bib0042","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1878-0261.13582","article-title":"The fatty acid synthase (FASN) signalome: a molecular guide for precision oncology","volume":"18","author":"Menendez","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.neo.2025.101143_bib0043","first-page":"2523","article-title":"Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma","volume":"27","author":"Alo","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.neo.2025.101143_bib0044","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.4161\/cc.7.19.6719","article-title":"Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome","volume":"7","author":"Witkiewicz","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.neo.2025.101143_bib0045","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1158\/1055-9965.EPI-09-0144","article-title":"Serum fatty acid synthase as a marker of pancreatic neoplasia","volume":"18","author":"Walter","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.neo.2025.101143_bib0046","first-page":"89","article-title":"Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers","volume":"2","author":"Yang","year":"2011","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"10.1016\/j.neo.2025.101143_bib0047","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1158\/0008-5472.CAN-16-3062","article-title":"De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer","volume":"77","author":"Tadros","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101143_bib0048","first-page":"2211","article-title":"Upregulation of pyruvate kinase M2 expression by fatty acid synthase contributes to gemcitabine resistance in pancreatic cancer","volume":"15","author":"Tian","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.neo.2025.101143_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.neo.2025.101143_bib0050","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neo.2025.101143_bib0051","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-22-2807","article-title":"Phase II investigation of TVB-2640 (Denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101143_bib0052","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/s41419-021-04262-x","article-title":"Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells","volume":"12","author":"Schroeder","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neo.2025.101143_bib0053","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.97.7.3450","article-title":"Synthesis and antitumor activity of an inhibitor of fatty acid synthase","volume":"97","author":"Kuhajda","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neo.2025.101143_bib0054","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/chir.22139","article-title":"Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity","volume":"25","author":"Makowski","year":"2013","journal-title":"Chirality"},{"key":"10.1016\/j.neo.2025.101143_bib0055","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/14728222.2017.1381087","article-title":"Fatty acid synthase (FASN) as a therapeutic target in breast cancer","volume":"21","author":"Menendez","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neo.2025.101143_bib0056","doi-asserted-by":"crossref","first-page":"11355","DOI":"10.1096\/fj.202000705R","article-title":"Inhibitors of lipogenic enzymes as a potential therapy against cancer","volume":"34","author":"Montesdeoca","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.neo.2025.101143_bib0057","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1101\/sqb.2016.81.030841","article-title":"To prime, or not to prime: that is the question","volume":"81","author":"Potter","year":"2016","journal-title":"Cold. Spring. Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.neo.2025.101143_bib0058","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.matbio.2018.01.020","article-title":"BH3 mimetics as anti-fibrotic therapy: Unleashing the mitochondrial pathway of apoptosis in myofibroblasts","volume":"68-69","author":"Kuehl","year":"2018","journal-title":"Matrix. Biol."},{"key":"10.1016\/j.neo.2025.101143_bib0059","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","article-title":"Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases","volume":"16","author":"Hinz","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.neo.2025.101143_bib0060","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/14728222.2017.1349754","article-title":"Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer","volume":"21","author":"Guikema","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neo.2025.101143_bib0061","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219398","article-title":"Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment","volume":"14","author":"Britt","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2025.101143_bib0062","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1126\/science.288.5475.2379","article-title":"Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors","volume":"288","author":"Loftus","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neo.2025.101143_bib0063","doi-asserted-by":"crossref","first-page":"9498","DOI":"10.1073\/pnas.132128899","article-title":"C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity","volume":"99","author":"Thupari","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neo.2025.101143_bib0064","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ebiom.2015.06.020","article-title":"Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression","volume":"2","author":"Ventura","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neo.2025.101143_bib0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ebiom.2016.12.012","volume":"16","author":"Heuer","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neo.2025.101143_bib0066","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1038\/s41467-023-39266-y","article-title":"Atomic model for core modifying region of human fatty acid synthase in complex with Denifanstat","volume":"14","author":"Hasan","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2025.101143_bib0067","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nchembio.1603","article-title":"A human fatty acid synthase inhibitor binds \u03b2-ketoacyl reductase in the keto-substrate site","volume":"10","author":"Hardwicke","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neo.2025.101143_bib0068","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1242\/jcs.031682","article-title":"Control of mitochondrial apoptosis by the Bcl-2 family","volume":"122","author":"Brunelle","year":"2009","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.neo.2025.101143_bib0069","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/cdd.2017.179","article-title":"MOMP, cell suicide as a BCL-2 family business","volume":"25","author":"Kalkavan","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.neo.2025.101143_bib0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s000180300001","article-title":"Molecular mechanisms of N-acetylcysteine actions","volume":"60","author":"Zafarullah","year":"2003","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.neo.2025.101143_bib0071","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2131\/jts.36.775","article-title":"Antioxidant N-acetyl-L-cysteine (NAC) supplementation reduces reactive oxygen species (ROS)-mediated hepatocellular tumor promotion of indole-3-carbinol (I3C) in rats","volume":"36","author":"Shimamoto","year":"2011","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.neo.2025.101143_bib0072","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1006\/bbrc.1998.9729","article-title":"Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production","volume":"253","author":"Li","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neo.2025.101143_bib0073","doi-asserted-by":"crossref","first-page":"47726","DOI":"10.1074\/jbc.M406314200","article-title":"Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress","volume":"279","author":"Riganti","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neo.2025.101143_bib0074","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41392-020-00326-0","article-title":"NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications","volume":"5","author":"Ju","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.neo.2025.101143_bib0075","doi-asserted-by":"crossref","first-page":"32576","DOI":"10.18632\/oncotarget.15936","article-title":"NADPH accumulation is responsible for apoptosis in breast cancer cells induced by fatty acid synthase inhibition","volume":"8","author":"Cui","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2025.101143_bib0076","first-page":"390","article-title":"Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53","volume":"9","author":"Cheng","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.neo.2025.101143_bib0077","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1111\/cas.15962","article-title":"Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines","volume":"114","author":"Masuo","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.neo.2025.101143_bib0078","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1535-7163.MCT-21-0474","article-title":"Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL-specific degrader DT2216","volume":"21","author":"Thummuri","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2025.101143_bib0079","doi-asserted-by":"crossref","first-page":"62533","DOI":"10.18632\/oncotarget.11530","article-title":"Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature","volume":"7","author":"Jung","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2025.101143_bib0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/gutjnl-2016-313133","article-title":"Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility","volume":"67","author":"Knudsen","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.neo.2025.101143_bib0081","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3390\/cancers12051327","article-title":"Patient-derived xenograft models of pancreatic cancer: overview and comparison with other types of models","volume":"12","author":"Garcia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2025.101143_bib0082","doi-asserted-by":"crossref","unstructured":"Dreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki EM, Dray E, Serrels B, Caligiuri G, Rebus S, Plenker D, Galluzzo Z, Brunton H, Cunningham R, Tesson M, Nourse C, Bailey UM, Jones M, Moran-Jones K, Wright DW, Duthie F, Oien K, Evers L, McKay CJ, McGregor GA, Gulati A, Brough R, Bajrami I, Pettitt S, Dziubinski ML, Candido J, Balkwill F, Barry ST, Gr\u00fctzmann R, Rahib L; Glasgow Precision Oncology Laboratory; Australian Pancreatic Cancer Genome Initiative; Johns A, Pajic M, Froeling FEM, Beer P, Musgrove EA, Petersen GM, Ashworth A, Frame MC, Crawford HC, Simeone DM, Lord C, Mukhopadhyay D, Pilarsky C, Tuveson DA, Cooke SL, Jamieson NB, Morton JP, Sansom OJ, Bailey PJ, Biankin AV, Chang DK. Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology. 2021;160:362\u201377.e13.","DOI":"10.1053\/j.gastro.2020.09.043"},{"key":"10.1016\/j.neo.2025.101143_bib0083","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101143_bib0084","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer","volume":"16","author":"Collisson","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.neo.2025.101143_bib0085","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/gutjnl-2014-308350","article-title":"Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue","volume":"65","author":"Sagar","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.neo.2025.101143_bib0086","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.1158\/1078-0432.CCR-19-0799","article-title":"Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to chemotherapy by abrogating the TopBP1\/ATR-mediated DNA damage Response","volume":"25","author":"Ding","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101143_bib0087","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1074\/jbc.M112.386102","article-title":"Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent mechanism, functions as a prosurvival molecule in cancer","volume":"288","author":"Gogada","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neo.2025.101143_bib0088","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","article-title":"PUMA, a novel proapoptotic gene, is induced by p53","volume":"7","author":"Nakano","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.neo.2025.101143_bib0089","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","article-title":"Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis","volume":"288","author":"Oda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neo.2025.101143_bib0090","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1038\/s41467-019-13028-1","article-title":"Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells","volume":"10","author":"Bueno","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2025.101143_bib0091","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.sbi.2019.03.001","article-title":"Structure and mechanisms of ROS generation by NADPH oxidases","volume":"59","author":"Magnani","year":"2019","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.neo.2025.101143_bib0092","first-page":"890","article-title":"NADPH oxidases (NOX): an overview from discovery","volume":"10","author":"Vermot","year":"2021","journal-title":"Mol. Mech. Physiol. Pathol. Antioxidants (Basel)."},{"key":"10.1016\/j.neo.2025.101143_bib0093","doi-asserted-by":"crossref","first-page":"11632","DOI":"10.1021\/acs.jmedchem.3c00770","article-title":"NADPH Oxidases: from molecular mechanisms to current inhibitors","volume":"66","author":"Cipriano","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neo.2025.101143_bib0094","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000555","article-title":"Elimination of NADPH oxidase activity promotes reductive stress and sensitizes the heart to ischemic injury","volume":"3","author":"Yu","year":"2014","journal-title":"J. Am. Heart. Assoc."},{"key":"10.1016\/j.neo.2025.101143_bib0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/ars.2017.7216","article-title":"NAD(H) and NADP(H) redox couples and cellular energy metabolism","volume":"28","author":"Xiao","year":"2018","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.neo.2025.101143_bib0096","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1089\/ars.2019.7803","article-title":"Metabolic responses to reductive stress","volume":"32","author":"Xiao","year":"2020","journal-title":"Antioxid. Redox. Signal"},{"key":"10.1016\/j.neo.2025.101143_bib0097","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/cells10040758","article-title":"Role of reductive versus oxidative stress in tumor progression and anticancer drug resistance","volume":"10","author":"Chun","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neo.2025.101143_bib0098","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/164_2020_387","article-title":"NOX Inhibitors: from bench to Naxibs to bedside","volume":"264","author":"Elbatreek","year":"2021","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neo.2025.101143_bib0099","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1089\/ars.2013.5814","article-title":"Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement","volume":"23","author":"Altenh\u00f6fer","year":"2015","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.neo.2025.101143_bib0100","doi-asserted-by":"crossref","first-page":"eabc7405","DOI":"10.1126\/scisignal.abc7405","article-title":"Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics","volume":"14","author":"Daniels","year":"2021","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neo.2025.101143_bib0101","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1476-4598-7-64","article-title":"Apoptotic pathways in pancreatic ductal adenocarcinoma","volume":"7","author":"Hamacher","year":"2008","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neo.2025.101143_bib0102","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1038\/cddis.2014.6","article-title":"Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer","volume":"5","author":"Nakajima","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neo.2025.101143_bib0103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219398","article-title":"Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment","volume":"14","author":"Britt","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2025.101143_bib0104","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1111\/cas.14569","article-title":"Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small-cell lung cancer cells","volume":"111","author":"Ohgino","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.neo.2025.101143_bib0105","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/1535-7163.MCT-14-0291","article-title":"Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth","volume":"13","author":"Pal","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2025.101143_bib0106","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41586-021-03828-1","article-title":"Highly accurate protein structure prediction for the human proteome","volume":"596","author":"Tunyasuvunakool","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101143_bib0107","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/ja026939x","article-title":"HADDOCK: a protein-protein docking approach based on biochemical or biophysical information","volume":"125","author":"Dominguez","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neo.2025.101143_bib0108","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jmb.2015.09.014","article-title":"The HADDOCK2.2 Web server: user-friendly integrative modeling of biomolecular complexes","volume":"428","author":"van Zundert","year":"2016","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.neo.2025.101143_bib0109","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/jcc.21759","article-title":"Effect of the damping function in dispersion corrected density functional theory","volume":"32","author":"Grimme","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neo.2025.101143_bib0110","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1021\/acs.jctc.2c00230","article-title":"PyRESP: a program for electrostatic parameterizations of additive and induced dipole polarizable force fields","volume":"18","author":"Zhao","year":"2022","journal-title":"J. Chem. Theory. Comput."},{"key":"10.1016\/j.neo.2025.101143_bib0111","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1756-0500-5-367","article-title":"ACPYPE - AnteChamber PYthon parser interfacE","volume":"5","author":"Sousa da Silva","year":"2012","journal-title":"BMC. Res. Notes."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T09:56:08Z","timestamp":1741946168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":111,"alternative-id":["S1476558625000223"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101143","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101143"}}